News

CDC commentary claims patients taken off opiods too soon.

A new report determines the trends fueling drug research and development over the past 10 years-and into the future.

As a healthcare executive, it’s your job to excite and inspire your leadership team to bring their A-game. Here are six powerful ways.

Patients taking heart medications are most at risk when a pharmacy shuts its doors.

The first step to tackling one of healthcare’s biggest problems is to gain more complete access to patient data.

The growing availability of direct-to-consumer genetic tests highlights the need for validating and interpreting the tests’ results.

FDA cleared the first medical device to treat attention deficit hyperactivity disorder (ADHD) in kids.

How do healthcare executives stay passionate about coming to work and keeping things positive and new? Managed Healthcare Executive asked 15 of them, and here’s what they said.

Five surprising updates about one of healthcare’s top trends.

A Commonwealth Fund study has revealing findings about PBMs’ use of rebates and impact on drug prices.

How technologies are helping health systems think about-and mobilize on-social determinants of health.

Healthcare experts weigh in on what we can expect in 2019 and beyond.

The real-world strategies used to manage the high cost of specialty meds.

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

Metastatic breast cancer drug expands treatment to men.

Technical skills aren’t enough to effectively manage an organization-you need other skills they don’t teach in school.

A complex disease such as diabetes requires a team-based approach to help patients comply with their regimen.

After his mother’s journey with breast cancer, Scott Rissmiller discovered the deep desire to make an impact in others’ lives as a physician-leader.

While it is difficult work, provider engagement is attainable. Here are some strategies that health systems can use to successfully engage their physicians.

What health execs need to know about the drugs and policies affecting spending.

The disease management and insurer initiatives changing the diabetes landscape.

FDA fast-tracks biosimiliar insulin products to elevate competition.

Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.

What the future of specialty drugs holds for healthcare.

Gene therapy offers great hope for patients, but comes with a bevy of challenges for patients and payers alike.

FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.